EU MDR Adds Aging Data Requirement for IVD Hardware Biocompatibility

On 28 April 2026, the European Medical Device Coordination Group (MDCG) issued MDCG 2026-12: Supplementary Guidance on Long-term Stability and Material Aging for Biocompatibility of IVD Hardware. This update introduces new biocompatibility revalidation requirements for in vitro diagnostic (IVD) hardware—such as assay kit housings, microfluidic chip substrates, and sample collection modules—intended for CE marking submissions after October 2027. The requirement is expected to impact manufacturers and suppliers involved in the design, production, and export of IVD hardware to the EU market.

Event Overview

On 28 April 2026, the MDCG published MDCG 2026-12, mandating that all IVD hardware submitted for CE marking after October 2027 must include full ISO 10993-1 biocompatibility revalidation reports following accelerated aging equivalent to ≥36 months. The guidance applies specifically to hardware components—not reagents or software—and covers physical parts in direct or indirect contact with clinical samples or users.

Which Subsectors Are Affected

IVD Hardware Manufacturers (OEMs and Contract Manufacturers)

These entities are directly responsible for generating and submitting compliance documentation. The requirement necessitates new aging protocols, extended testing timelines, and potential redesigns to ensure material stability over the claimed shelf life. Impact includes longer type-testing cycles, increased lab resource allocation, and higher upfront validation costs before submission.

Material and Component Suppliers

Suppliers of plastics, polymers, adhesives, or molded parts used in IVD hardware must now provide enhanced material specifications—including aging performance data under ISO 10993-1-relevant conditions. Without such data, OEMs may be unable to complete required biocompatibility revalidation, creating a bottleneck in the supply chain.

CE Marking Consultants and Notified Bodies

Consultants supporting IVD hardware submissions will need to revise their technical file review checklists and update client guidance. Notified Bodies will likely adjust audit criteria to verify aging methodology, equivalence justification, and test report completeness—potentially extending assessment timelines for affected devices.

Export-Focused Distributors and Trade Agents

Distributors acting as EU Authorised Representatives or supporting CE submissions for non-EU manufacturers must ensure that incoming technical documentation meets the new aging-related biocompatibility expectations. Failure to confirm alignment may delay market access or trigger post-submission requests for supplementary evidence.

What Relevant Enterprises or Practitioners Should Focus On and How to Respond

Monitor official updates from MDCG and EU Commission

The current guidance is issued as a recommendation, not binding legislation. Analysis shows that its enforceability depends on future alignment with Annex II/III of Regulation (EU) 2017/746 and any subsequent amendments to harmonised standards. Stakeholders should track upcoming revisions to EN ISO 10993-1 and related guidance documents.

Prioritise evaluation of high-volume or long-shelf-life hardware categories

Observably, the impact is most acute for hardware with declared shelf lives exceeding 24 months—or those using polymers known to undergo hydrolytic, oxidative, or UV-induced degradation (e.g., certain polypropylenes, PC, or COC). Companies should identify such products early and initiate aging protocol development accordingly.

Distinguish between policy signal and implementation readiness

From industry perspective, this requirement signals a tightening of biological safety expectations for structural IVD components—but it does not yet reflect an immediate change in conformity assessment practice. Submissions before October 2027 remain governed by prior interpretation; however, preparing ahead avoids last-minute bottlenecks once the deadline approaches.

Initiate internal alignment across R&D, QA, and procurement functions

Current more appropriate action is cross-functional planning: R&D to define aging parameters, QA to validate test methods, and procurement to engage suppliers for aging-compatible material declarations. Delaying these steps risks misalignment when technical files are assembled for submission.

Editorial Perspective / Industry Observation

This update is better understood as a regulatory signal than an immediate operational shift. Analysis shows that MDCG guidance often precedes formal standard updates or Notified Body practice notes by 6–12 months. Its publication reflects growing scrutiny of long-term material behaviour—not just initial biocompatibility—and aligns with broader trends in regulatory science, including increased emphasis on real-world use conditions. From industry angle, it underscores that hardware compliance is no longer assessed in isolation from time-dependent material changes. Continued observation is warranted as EU authorities clarify how ‘equivalent to ≥36 months’ will be demonstrated (e.g., via Arrhenius modeling, real-time studies, or comparative benchmarks).

Conclusion

This requirement marks a procedural escalation in the evidentiary burden for IVD hardware CE marking—not a fundamental change in scope or classification. It reinforces that biological safety assessments must now account for aging effects, particularly for components intended for multi-year shelf life. For stakeholders, the current priority is not reactive compliance, but proactive preparation: mapping affected products, engaging material suppliers, and building internal capability for aging-informed biocompatibility planning. The timeline allows for phased implementation, but delays in foundational work may compress later-stage submission windows.

Information Sources

Main source: MDCG 2026-12, published by the European Medical Device Coordination Group on 28 April 2026. Ongoing developments—including potential incorporation into EU Commission guidelines or harmonised standards—remain subject to observation and are not yet confirmed.